- Novartis AG NVS has halted a Phase 2 trial of CFZ533 (iscalimab) in kidney transplant patients.
- The decision follows interim data that showed iscalimab was not as good as tacrolimus-based treatment in preventing organ rejection.
- Iscalimab's study in liver transplant continues, and additional studies exploring the drug as a potential treatment in other conditions.
- Novartis is continuing to review the data from the CIRRUS-1 study. Once complete, the company will share the results with the broader scientific community.
- Price Action: NVS shares closed 0.54% lower at $92.15 on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
